Cargando…
Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette–Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study
The irradiated, allogeneic, cellular CSF-470 vaccine plus Bacillus Calmette–Guerin (BCG) and recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) is being tested against medium-dose IFN-α2b in stages IIB–III cutaneous melanoma (CM) patients (pts) after surgery in an open, ra...
Autores principales: | Mordoh, José, Pampena, María Betina, Aris, Mariana, Blanco, Paula Alejandra, Lombardo, Mónica, von Euw, Erika María, Mac Keon, Soledad, Yépez Crow, Michelle, Bravo, Alicia Inés, O’Connor, Juan Manuel, Orlando, Ana Gabriela, Ramello, Franco, Levy, Estrella Mariel, Barrio, María Marcela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449770/ https://www.ncbi.nlm.nih.gov/pubmed/28620382 http://dx.doi.org/10.3389/fimmu.2017.00625 |
Ejemplares similares
-
Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro Analysis of Immune Recruitment and Cytokine Release
por: Pampena, María B., et al.
Publicado: (2017) -
Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report
por: Aris, Mariana, et al.
Publicado: (2018) -
Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants
por: Pampena, María B., et al.
Publicado: (2018) -
Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF
por: Podaza, Enrique, et al.
Publicado: (2020) -
Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
por: Juliá, Estefanía Paula, et al.
Publicado: (2018)